A Gaiger,D Heintel,U Jger - 《European Journal of Clinical Investigation》 被引量: 5发表: 2015年 Agnogenic Myeloid Metaplasia Terminating in Acute Megakaryoblastic Leukemia T- and B-lymphocytes have been studied in 36 patients with chronic lymphatic leukaemia (CLL). Each 12 cases remained untre...
Dallapiccola B, Alimena G, Chessa L, Gastaldi R, De Rossi G, Semenzato G, Quinti I, Pandolfi F (1984): Chromosome stud- ies in patients with T-CLL chronic lymphatic leukemia and expansions of granular lymphocytes. Int J Cancer 34:171- 176....
目的探讨胸腺肽α1对老年B细胞性慢性淋巴细胞白血病(B cell chronic lymphatic leukemia,B-CLL)患者来源的细胞因子诱导的杀伤细胞(cytokine induced killer cells,CIK... 蔡力力,杨波,迟小华,... - 《军医进修学院学报》 被引量: 0发表: 2012年 慢性淋巴细胞白血病分层治疗的长期疗效观察 其中A期2例,B期4例,...
When used as a minimal residual disease (MRD)–guided treatment approach, ibrutinib (Imbruvica) combined with venetoclax (Venclexta) improved progression-free and overall survival (OS) compared with fludarabine, cyclophosphamide, and rituximab (Rituxan; FCR) in patients with treatment-naive ch...
Leukemia (2017) 31, 2085–2093; doi:10.1038/leu.2017.65 INTRODUCTION Chronic lymphocytic leukemia (CLL) is a lymphoproliferative disorder accounting for 30% of adult leukemia and 25% of non- Hodgkin lymphoma. CLL is the commonest form of leukemia above the age of 50 years with a median age...
Duration of ibrutinib and venetoclax, as determined by the patient’s minimal residual disease, improved survival in patients with treatment-naïve chronic lymphocytic leukemia. At a duration determined by the patient’s minimal residual disease (MRD), ibrutinib (Imbruvica) and venetoclax...
Krutle,A. Krber 摘要: Treatment of B-cell chronic lymphocytic leukemia (B-CLL) in stage Binet-A irrespective of risk factors or disease progression has not been shown to improve overall or progression free survival. Therefore, the CLL1 trial of the German CLL Study Group (DCLLSG) tests ...
Minimal residual disease detection after myeloablative chemotherapy in chronic lymphatic leukemia. J Mol Med 1999; 77: 259–265. Article CAS PubMed Google Scholar Michallet M, Thiebaut A, Dreger P, Remes K, Milpied N, Santini G et al. Peripheral blood stem cell (PBSC) mobilization and ...
Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: A German multicenter phase II study and immunosuppressive effects of fludarabine and epirubicin in the treatment of CLL in Binet stages B and C as first-line therapy or in first relapse. ... MJ Rummel,G Kfer,M P...
Chronic Lymphocytic Leukemia (CLL) is a B-lymphoproliferative disorder, characterized by the proliferation and accumulation of CD19/CD5-positive B cells in the peripheral blood, lymphatic organs, and bone marrow of patients [1]. Due to the heterogeneity in clinical manifestations and clinical course...